{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:19:20Z","timestamp":1769087960306,"version":"3.49.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3184,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>European Association of Cardiovascular Imaging\/Heart Failure Association Cardiac Oncology Toxicity Registry was launched in October 2014 as a European Society of Cardiology multicentre registry of breast cancer patients referred to imaging laboratories for routine surveillance, suspected, or confirmed anticancer drug-related cardiotoxicity (ADRC). After a pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol (version 1.0) and electronic case report form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Main changes of the version 2.0 concerned exclusion criteria, registry duration, and clarification of the population characteristics. Breast cancer radiotherapy has been removed as an exclusion criterion, which involves now only history of a pre-chemotherapy left ventricular dysfunction. The period for long-term registry recruitment has been reduced (December 2017), but the target study population was extended to 3000 patients. The characteristics of the population are now better defined: patients seen in an imaging lab, which will include patients undergoing chemotherapy with associated targeted therapy or no targeted therapy, at increased risk of ADRC. In total, 1294 breast cancer patients have been enrolled, and 783 case report forms locked from October 2014 to November 2016. Of these, 481 (61.4%) were seen at first evaluation and 302 (38.6%) while on oncologic treatment with anticancer drugs. Fifty-two patients (17.2%) were not in targeted therapies, 191 (63.3%) were ongoing targeted therapy, and 59 (19.5%) had completed it. Twenty-three (2.9%) patients had a suspected diagnosis and 35 (4.5%) a confirmed diagnosis of ADRC. Arterial hypertension was the most prevalent cardiovascular risk factor (29.2%) followed by diabetes (6.1%). Previous history of heart failure accounted for 0.5%, whereas previous cardiac disease was identified in 6.3% of population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The changes of the original protocol of the COT Registry and first update allow a first glance to the panorama of cardiovascular characteristics of breast cancer patients enrolled.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12162","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T13:22:54Z","timestamp":1493731374000},"page":"312-318","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Protocol Update and Preliminary Results of EACVI\/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology"],"prefix":"10.1093","volume":"4","author":[{"given":"Patrizio","family":"Lancellotti","sequence":"first","affiliation":[{"name":"University of Li\u00e8ge Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology , Li\u00e8ge ,","place":["Belgium"]},{"name":"Gruppo Villa Maria Care and Research, Anthea Hospital , Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Galderisi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University Hospital , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[{"name":"Cardiologie, LTSI-INSERM U 1099, CHU Rennes, Universit\u00e9 Rennes 1 , Rennes ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Edvardsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital, Rikshospitalet, University of Oslo , Oslo ,","place":["Norway"]},{"name":"Centre of Cardiological Innovation , Oslo ,","place":["Norway"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogdan A.","family":"Popescu","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases \u2018Prof. Dr. C. C. Iliescu\u2019, University of Medicine and Pharmacy \u2018Carol Davila\u2019\u2014Euroecolab , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, University Hospital \u2018Attikon\u2019, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, University Hospital \u2018Attikon\u2019, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[{"name":"URMITE, Aix Marseille Universit\u00e9, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU - M\u00e9diterran\u00e9e Infection"},{"name":"APHM, La Timone Hospital, Cardiology Department , Marseille ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Lestuzzi","sequence":"additional","affiliation":[{"name":"Centro di Riferimento Oncologico (CRO), National Cancer Institute , Aviano ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciro","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University Hospital , Naples ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Moonen","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology , Li\u00e8ge ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CHU Sart Tilman Li\u00e8ge, University of Li\u00e8ge , Li\u00e8ge ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryna","family":"Andarala","sequence":"additional","affiliation":[{"name":"ESC EORP Department , Sophia Antipolis ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University Medicine G\u00f6ttingen (UMG) , G\u00f6ttingen ,","place":["Germany & DZHK (German Center for Cardiovascular Research)"]},{"name":"Division of Cardiology and Metabolism \u2013 Heart Failure, Cachexia & Sarcopenia; Department of Internal Medicine & Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charit\u00e9 University Medicine , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"2026012115133653100_ehf212162-bib-0001","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026012115133653100_ehf212162-bib-0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ehf2.12048","article-title":"The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer. Expecting the unexpected: right atrial mass in a transplant patient","volume":"2","author":"Murbraech","year":"2015","journal-title":"ESC Heart Fail"},{"key":"2026012115133653100_ehf212162-bib-0003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026012115133653100_ehf212162-bib-0004","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115133653100_ehf212162-bib-0005","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1470-2045(07)70246-2","article-title":"Recent cancer survival in Europe: a 2000\u201302 period analysis of EUROCARE-4 data","volume":"8","author":"Verdecchia","year":"2007","journal-title":"Lancet Oncol"},{"key":"2026012115133653100_ehf212162-bib-0006","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jnci\/djt161","article-title":"Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer","volume":"105","author":"Brower","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2026012115133653100_ehf212162-bib-0007","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012115133653100_ehf212162-bib-0008","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115133653100_ehf212162-bib-0009","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ehjci\/jev024","article-title":"EACVI\/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI\/HFA COT Registry)\u2014EURObservational Research Program of the European Society of Cardiology","volume":"16","author":"Lancellotti","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115133653100_ehf212162-bib-0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multi-modality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012115133653100_ehf212162-bib-0011","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1056\/NEJMoa1209825","article-title":"Ischemic heart disease after breast cancer radiotherapy","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012115133653100_ehf212162-bib-0012","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1200\/JCO.1998.16.11.3493","article-title":"Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients","volume":"16","author":"Shapiro","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026012115133653100_ehf212162-bib-0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djk064","article-title":"Long-term risk of cardiovascular disease in 10-year survivors of breast cancer","volume":"99","author":"Hooning","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2026012115133653100_ehf212162-bib-0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128891","article-title":"Metabolic syndrome and breast cancer risk: a case-cohort study nested in a multicentre Italian cohort","volume":"10","author":"Agnoli","year":"2015","journal-title":"PLoS One"},{"key":"2026012115133653100_ehf212162-bib-0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ehf2.12035","article-title":"Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure","volume":"2","author":"Doehner","year":"2015","journal-title":"ESC Heart Fail"},{"key":"2026012115133653100_ehf212162-bib-0016","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/CCO.0000000000000132","article-title":"An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity","volume":"26","author":"Bhave","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"2026012115133653100_ehf212162-bib-0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2459\/JCM.0b013e328365afb5","article-title":"Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer","volume":"15","author":"Russo","year":"2014","journal-title":"J Cardiovasc Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/3\/312\/66256823\/eschf_4_3_312.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/4\/3\/312\/66256823\/eschf_4_3_312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:18:27Z","timestamp":1769026707000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/4\/3\/312\/8413091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,5,2]]},"published-print":{"date-parts":[[2017,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12162","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,8]]},"published":{"date-parts":[[2017,5,2]]},"assertion":[{"value":"2017-01-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}